- Home
- PCRX vs HTZ Comparison
PCRX vs HTZ Comparison
Compare PCRX & HTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- HTZ
- Stock Information
- Founded
- PCRX 2006
- HTZ 1918
- Country
- PCRX United States
- HTZ United States
- Employees
- PCRX N/A
- HTZ N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- HTZ Rental/Leasing Companies
- Sector
- PCRX Health Care
- HTZ Consumer Discretionary
- Exchange
- PCRX Nasdaq
- HTZ Nasdaq
- Market Cap
- PCRX 1.1B
- HTZ 1.3B
- IPO Year
- PCRX 2011
- HTZ 1997
- Fundamental
- Price
- PCRX $24.65
- HTZ $8.24
- Analyst Decision
- PCRX Buy
- HTZ Sell
- Analyst Count
- PCRX 9
- HTZ 8
- Target Price
- PCRX $30.11
- HTZ $4.28
- AVG Volume (30 Days)
- PCRX 1.2M
- HTZ 27.5M
- Earning Date
- PCRX 05-06-2025
- HTZ 05-12-2025
- Dividend Yield
- PCRX N/A
- HTZ N/A
- EPS Growth
- PCRX N/A
- HTZ N/A
- EPS
- PCRX N/A
- HTZ N/A
- Revenue
- PCRX $700,966,000.00
- HTZ $9,049,000,000.00
- Revenue This Year
- PCRX $9.48
- HTZ $2.20
- Revenue Next Year
- PCRX $11.31
- HTZ $1.89
- P/E Ratio
- PCRX N/A
- HTZ N/A
- Revenue Growth
- PCRX 3.85
- HTZ N/A
- 52 Week Low
- PCRX $11.16
- HTZ $2.47
- 52 Week High
- PCRX $31.67
- HTZ $8.74
- Technical
- Relative Strength Index (RSI)
- PCRX 51.22
- HTZ 79.12
- Support Level
- PCRX $24.10
- HTZ $3.61
- Resistance Level
- PCRX $25.35
- HTZ $4.06
- Average True Range (ATR)
- PCRX 1.49
- HTZ 0.60
- MACD
- PCRX 0.01
- HTZ 0.35
- Stochastic Oscillator
- PCRX 48.89
- HTZ 90.46
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About HTZ Hertz Global Holdings Inc
Hertz Global Holdings Inc is engaged principally in the business of renting vehicles through Hertz, Dollar and Thrifty brands. The Company has identified two reportable segments: Americas RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in the U.S., Canada, Latin America and the Caribbean; International RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in locations other than the U.S., Canada, Latin America and the Caribbean. The Company maintain a substantial network of company-operated rental locations, a majority of which are in Europe, and have franchisees and partners that operate rental locations under brands. Geographical markets includes U.S., Europe, Pacific Asia, Middle East and Africa, Latin America.